Introduction
Approximately 1% of the human genome consists of sequences with homologies to exogenous retroviruses. These human endogenous retroviral (HERV) elements integrated into the germline of predecessor primate species several million years ago. The vast majority of HERV sequences are dysfunctional due to the accumulation of multiple nonsense mutations. However, proviral loci of the HERV-K (HML-2) family of retroviral elements, of which 30 to 50 copies are estimated to reside in the haploid human genome, often contain intact open reading frames for the viral proteins Gag, Prt, Pol and Env (Lower et al., 1993; Mayer et al., 1997a,b) . We have recently identi®ed an almost intact HERV-K provirus on human chromosome 7 (Mayer et al., 1999) .
Germ cell tumors (GCTs) and GCT cell lines express complex splicing patterns of HERV-K (HML-2) transcripts reminiscent of the patterns observed upon infection with exogenous lentiviruses (Lower et al., 1993) . GCTs produce large quantities of Gag protein (Sauter et al., 1995) and up to 85% of the patients with GCT produce antibodies directed against the viral Env protein whereas healthy individuals and patients with in¯ammatory diseases or tumors other than GCT very rarely develop such antibodies. Antibodies against a de®ned domain of Env, the transmembrane (TM) domain, are exclusively associated with GCT . All ®ndings combined indicate that HERV proteins, and in particular the TM domain of Env, constitute markers speci®c for GCT but leave open the possibility that individual proteins exert functions that actively contribute to tumorigenesis. The env gene contains a central open reading frame (cORF) which, as a result of alternative splicing, can give rise to cORF, a functional homologue of the regulatory Rev/Rex proteins of HIV and HTLV (Lower et al., 1995; Magin et al., 1999; Yang et al., 1999) .
Mice de®cient for the PLZF protein show testicular hypertrophy and are sterile due to impaired spermatogenesis (Hawe et al., 1996) . However, PLZF was ®rst implicated in certain leukemias. Acute promyelocytic leukemia (APL) is characterized by the fusion of one of the following ®ve genes to the RARa (retinoic acid receptor alpha)-gene: PLZF (t11/17 q23;q21), PML (promyelocytic leukemia, t15/17), NuMA (nuclear mitotic apparatus, t11/17 q13;q21), NPM (nucleophosmin, t5/17) or Stat5b (Chen et al., 1993a,b; de The et al., 1990; Wells et al., 1997; Redner et al., 1996; Arnould et al., 1999) . All translocations result in an impaired retinoic acid dierentiation pathway due to the expression of an aberrant retinoic acid receptor (reviewed in Melnick and Licht, 1999) . t11/17-APL involving PLZF-RARa fusions is relatively rare, but the clinical prognosis is poor: While a high percentage of APLs associated with the other RARa fusion partners can be cured by treatment with high doses of all-trans retinoic acid, no such response is seen if PLZF is involved (Guidez et al., 1994) .
PLZF structurally resembles the POZ (Pox virus and Zinc ®nger)-domain zinc-®nger proteins, a family of transcription factors. It recognizes speci®c DNA sequences via its C-terminal zinc ®nger domain consisting of nine KruÈ ppel-like C2H2 elements (Li et al., 1997) . However, PLZF does not function as a transactivator; rather, target genes are suppressed upon DNA binding by the interaction of the N-terminal POZ domain with the co-repressors N-CoR, SMRT, Sin3A and HDAC1 (histone deacetylase 1; Hong et al., 1997; He et al., 1998; Lin et al., 1998; Grignani et al., 1998; David et al., 1998) . Other factors bind to PLZF and may modulate its function as a transcriptional repressor (Melnick and Licht, 1999) . PLZF is a negative regulator of the cell cycle, a function which may at least in part be attributed to its negative eect on cyclin A2 expression (Yeyati et al., 1999) . Cyclin A2, the ®rst gene shown to be directly regulated by PLZF, seems to have a distinct function in murine testis development (Ravnik and Wolgemuth, 1999) . Particularly high levels of PLZF protein are observed in early hematopoietic progenitor cells, and PLZF levels decrease when the progenitor cells are induced to dierentiate, suggesting that the repressor plays a role in hematopoietic dierentiation and proliferation processes (Reid et al., 1995) . Remarkably, PLZF is expressed in several human tissues, among them the testis (Zhang et al., 1999) . Of note, PLZF null mice neither display any apparent disturbance of hematopoiesis nor develop leukemia but instead show defects in limb and axial skeletal patterning (Barna et al., 2000) and in spermatogenesis and testis development (Hawe et al., 1996) . We report here that cORF, a protein encoded by human endogenous retroviruses transcribed in germ cell tumors, interacts with the PLZF transcriptional repressor.
Results

HERV-K cORF induces tumor formation in nude mice
Human endogenous retroviruses of the HERV-K (HML-2) family contain open reading frames (ORFs) and encode proteins against which serum antibodies have been detected speci®cally in patients with germ cell tumors (GCTs) (Sauter et al., 1995 . It was therefore interesting to ask whether these proteins are merely tumor markers or can contribute to tumor development. In a ®rst set of experiments, we studied the ability of dierent ORFs, when transduced by retroviral vectors, to transform Rat-1 ®broblasts. Retroviral producer cell lines were developed from 293GP cells by stable insertion of proviral sequences containing either no transgene or sequences consisting of the HERV-K (HML-2) gag gene, the full-length or a truncated env gene, or the cORF gene that derives from the env gene ( Figure 1a ). All vectors contained the neomycin phosphotransferase (neoR) gene as a selectable marker. The viruses were pseudotyped with the vesiculo stomatitis virus G protein to achieve high titers and to eciently infect a wide range of target cells. Freshly thawed Rat-1 ®broblasts were infected at a multiplicity of infection of approximately 5610 3 colony forming units (c.f.u.) per¯ask and cultures were selected only brie¯y (20 days) to avoid the enrichment for fast growing cells that might have accumulated additional mutations. HERV-K (HML-2) Gag protein was readily detectable in cells infected with gag vector; however, expression of Env and cORF was detectable only at the RNA level ( Figure 1b and data not shown). Nevertheless, stable transfection of a plasmid producing cORF from the strong CMV promoter in Raji cells allowed the detection of a protein of 14.7 kDa with polyclonal antibody 3086 ( Figure 1c ) as well as with cORF-speci®c monoclonal antibodies.
A subset of bulk-infected G418-resistant cells was analysed for proliferation in culture, another subset was injected subcutaneously into immunocompromized nude mice following standard protocols. We within 53 days (6/7 in the representative experiment shown in Figure 2b . All experiments were repeated and animals were evaluated at dierent time points after injection; data not shown). In paran sections, these tumors displayed in®ltration of the subcutaneous fat and occasionally in®ltration of skin appendages or skeletal muscle. The tumor cells were pleomorphic, oval to spindle shaped, with moderate amounts of slightly eosinophilic cytoplasm, and enlarged, pleomorphic, and hyperchromatic nuclei (Figure 3a) . Mitotic ®gures, occasionally atypical, were abundant. Occasional apoptotic ®gures were noted. In situ hybridization gave speci®c autoradiographic signals with the cORF probe in anti-sense orientation ( Figure  3c ) whereas the sense control probe produced only background signal (not shown). Unfortunately, we failed to detect cORF protein by immunostaining with antibody 3086 because of high non-speci®c background staining with cellular and extracellular protein prior to absorption and lack of detectable signal after absorption.
Remarkably and in agreement with cORF supporting transformation, the three tumors that arose in the three mice treated with full-length env-transduced cells produced the env splice variant cORF instead of Env. PCR and sequencing analysis showed that the cORF variant virus was already present in the Rat-1 cultures upon infection with bona ®de env-vector, and that a signi®cant fraction of the viruses released from the env virus-producer cells consisted of cORF variant virus as the result of splicing (Figure 2b and data not shown). However, when a splice-defective truncated env was employed, no cORF variants were detectable and the 20 mice that received these cells produced tumors only at background frequency (5/20). These and the background tumors produced at sites injected with vector-only cells (5/27) were small (less than 50 mm 3 ) and benign when inspected for pathological characteristics (Figures 2b and 3b ), and they failed to produce positive signals with cORF antisense probe in in situ hybridizations ( Figure 3d ). Together, these data indicate that cORF but not Env or Gag protein supports tumor formation when expressed in Rat-1 cells.
cORF is part of high molecular weight complexes
In a ®rst attempt to understand cORF function we searched for interacting cellular proteins. Lysate from Raji cells stably producing cORF was subjected to zone velocity analysis in a glycerol gradient. After ultracentrifugation, 15 fractions were collected and total protein was precipitated from these fractions. As a control, a mixture of three proteins of known molecular weight was cofractionated. Western blot analysis with antiserum 3086 detected cORF in the fraction that corresponds to its molecular weight (i.e. 14.7 kDa in Raji cells; fraction 15), but also in fractions that contain complexes of about 100 kDa and complexes of more than 300 kDa ( Figure 4 ). These sedimentation patterns imply that cORF forms high molecular weight complexes with other cellular proteins.
cORF associates with the promyelocytic leukemia zinc finger protein (PLZF) Retroviral regulatory and accessory gene products are often multifunctional and interact with a variety of cellular protein components. To identify binding partners, we screened a human testis cDNA-library using a construct that consists of the LexA DNAbinding domain fused to cORF as a bait (pNLexAcORF). This yeast two-hybrid screen identi®ed the Cterminal 429 amino acid residues of the PLZF protein fused to the GAL4 activation domain (pJG4-5-PLZF245) as a binding partner of cORF. The interaction passed several tests for speci®city; however, PLZF was able to stimulate the LexA promoter to some extent even in the absence of cORF. To overcome this diculty, the same PLZF fragment was inserted in the LexA fusion vector pEG202 (pEG202-PLZF245) and was tested for interaction with cORF now fused to the GAL4 activation domain (pJG4-5-cORF). Under these conditions, the associa- To further substantiate the association between cORF and PLZF, GST pulldown assays were performed. GST-cORF coupled to glutathione sepharose was incubated with in vitro-translated, radiolabelled full-length PLZF protein. GST-cORF associated with PLZF in this assay; however, the amount of PLZF protein precipitated by GST-cORF could be increased about ®vefold by mixing the in vitrotranslated PLZF with lysate from Raji-cells prior to incubation with GST-cORF (Figure 6a ). This suggests that other cellular binding partners or posttranslational modi®cation of PLZF stabilizes the interaction, a suggestion supported by our observation that the electrophoretic mobility of PLZF changes after the incubation with the native cell extract: in vitrotranslated PLZF runs as a molecule of 75 ± 80 kDa, whereas PLZF incubated with cell lysate gives rise to a signal of *90 kDa (Figure 6a and data not shown). Finally, co-immunoprecipitations were carried out. For this purpose, 10 7 Raji cells with no cORF or designed to stably express cORF were transiently electrotransfected with 10 mg of a plasmid producing PLZF. PLZF protein was precipitated from whole cell extracts after 24 h with an anti-PLZF antibody. Extracts from cells that lacked cORF, control-transfected cells or cORFcells that received PLZF plasmid but were not incubated with antibody failed to show cORF protein associated with PLZF ( Figure 6b , lanes 1, 2 and 4). In contrast, cORF was brought down from cell extracts containing PLZF plus cORF ( Figure 6b , lane 3). Combined, these results show that cORF binds to the C-terminus of PLZF in the yeast two-hybrid system and to full-length PLZF in GST pulldown and immunoprecipitation assays.
The protein interaction domains
To characterize the binding domains on cORF and PLZF we resorted again to the yeast two-hybrid system. Deleted fragments of the two proteins were employed to study binding of the respective partner protein ( Figure 5 ). Neither the C-terminal part of cORF from aa 47 to the end (cORF 47/105) nor the central part from aa 21 ± 75 (cORF 21/75) were alone able to bind PLZF. However, a cORF fragment beginning at aa 21 and ending at aa 87 (cORF 21/ 87) associated with PLZF as eciently as the fulllength protein. These results indicate that ecient PLZF binding requires two domains: one domain encompassing aa 21 ± 47, and a second ranging from aa 75 ± 87 (Figure 5a ). The originally identi®ed cORF-interacting C-terminal portion of PLZF comprises 429 aa from residue 245 ± 673 (PLZF 245) and contains a proline-rich domain (aa 245 ± 400) and nine zinc-®nger epitopes (aa 405 ± 609), of which the hindmost four are known to make contact with DNA (Melnick and . Neither the zinc ®nger domain (PLZF 395) nor the proline-rich domain (PLZF 245/399) by themselves were able to interact with cORF; rather, the prolinerich domain together with the adjacent ®ve zinc-®ngers (PLZF 245/543), excluding the DNA-binding zinc ®ngers, were required for ecient binding (Figure 5b) .
No antibodies to cORF detectable in patients with GCT
In previous analyses, Gag and Env antibodies were observed almost exclusively in GCT patients (Sauter et al., 1995 . We therefore asked whether antibodies to cORF can also be detected in such individuals. In a complementary study, sera prepared from 18 patients with GCT, six patients with unspeci®ed leukemia, ®ve patients each with acute lymphatic leukemia (ALL) I or II, and 61 individuals suering from ALL III were incubated with SF158 insect cells infected with cORFexpressing baculovirus. Antibody interaction with the SF158 cells was visualized and quanti®ed upon incubation with a FITC-labeled secondary antibody (Sigma) as described before . Con®rming previous ®ndings, one third of the GCT patients produced antibodies against Gag and all GCT individuals displayed antibodies against Env, whereas none of the leukemic patients were positive in these assays. In stark contrast, no cORF-directed antibodies were found in any of the patients (Table 1) . However, RT ± PCR speci®c for cORF transcript performed on tumor material from two of the GCT patients from Table 1 revealed the presence of the RNA. Whether the RNA is con®ned to the tumor cells or is also present in the surrounding tissue is not yet clear. Thus, cORF like Gag and Env may be expressed in GCT but, in contrast to Gag and Env, does not induce a detectable humoral response in the patients.
Discussion
We document here that cORF, a 15 kDa protein encoded by the C-terminal open reading frame within the env gene of human endogenous retrovirus (HERV) sequences, supports the formation of tumors by murine immortal cells in nude mice and physically associates with the promyelocytic leukemia zinc ®nger protein (PLZF) involved in leukemogenesis in humans and in spermatogenesis in mice. Our previous work has suggested a link between the expression of HERV sequences and the development of germ cell tumors (GCT) in humans (Sauter et al., 1995 ; it is therefore tempting to speculate that cORF is a relevant tumor susceptibility factor, possibly in conjunction with PLZF.
Endogenous retrovirus proteins have been implicated in tumorigenesis before. For instance, murine MCA205 tumor cells failed to produce tumors in immunocompetent mice but escaped immune rejection and generated tumors when tailored to express either the full-length Env protein or the transmembrane region (TM) of Env from the Moloney murine leukemia virus (Mangeney and Heidmann, 1998) . Of note in this context, serum antibodies directed against the TM of HERV-K Env were exclusively observed in GCT patients, whereas in the rare cases of serum antibodies against HERV-K(HML-2) proteins in individuals with other diseases, these were not directed against TM . Whether the Env protein of HERV-K expressed in GCT also supports the escape from immune rejection remains to be seen.
cORF shares its N-terminal 87 of the 105 amino acid residues with Env. This raises the possibility that both proteins can contribute to tumor formation, especially in light of the fact that the domain on cORF that makes contact with PLZF (aa 21 ± 87) is also present in the N-terminus of Env. However, retroviral Env proteins are usually associated with the cytoplasmic membrane, and the N-terminal domain protrudes into the extracellular space. In contrast, cORF and PLZF are exclusively located in the nucleus (Lower et al., 1995; Reid et al., 1995) . It is thus unlikely that Env interacts with PLZF. Whether Env, like cORF, can bind to PLZF under experimental conditions has not been studied. The promyelocytic zinc ®nger protein PLZF is a transcriptional repressor that was originally identi®ed as part of a fusion with the retinoic acid receptor alpha (RARa) implicated in acute promyelocytic leukemia (APL; Chen et al., 1993a,b) . In attempts to identify protein binding partners, several interacting proteins such as the co-repressors N-CoR, SMRT, Sin3A and HDAC1 were found to associate with the N-terminal POZ domain of PLFZ (Hong et al., 1997; He et al., 1998; Lin et al., 1998; Grignani et al., 1998; David et al., 1998) . cORF is the third PLZF binding partner aside from the promyelocytic leukemia protein (PML; Melnick and and the epsin 1 protein that has been shown to target the boundary region of the proline-rich domain and the proximal of the nine zinc®ngers. Like cORF, epsin 1 is a shuttle protein (Magin et al., 1999; Boese et al., 2000; Hyman et al., 2000) . PML/PLZF interaction may be important for the maintenance of the non-transformed phenotype of certain cell types; furthermore, the oncogenic PMLRARa hybrid proteins that are involved in more than 98% of APL are still able to bind PLZF and to translocate PLZF away from its nuclear domains to other nuclear sites (Koken et al., 1997) . It is thus conceivable that cORF may act oncogenic through the disruption of subcellular localization or of normal PLZF functions such as transcription repression. However, we failed to ®nd a direct eect of cORF on the repression of a PLZF-responsive reporter plasmid in transient transfection studies (data not shown). It is thus likely that the eect of cORF on PLZF is more subtle.
PLZF fused to RARa is clearly involved in a subfraction of APL. Although the PLZF-RARa form of the disease is relatively rare among all APL, it carries a poor prognosis due to the lack of dierentiation induction in response to all-trans retinoic acid and apoptosis in response to As 2 O 3 (Guidez et al., 1994; Koken et al., 1999) . It is unclear at present whether cORF is involved in the development of leukemias. Patients with leukemic diseases were negative for HERV-K-directed serum antibodies (Sauter et al., 1995, 1996 and  Table 1 ). However, this does not exclude a role for cORF in this disease as the majority of oncoproteins involved in tumors fail to induce detectable humoral responses. Although all GCT patients examined in this study tested negative for antibodies against cORF as well, regardless of their strong and speci®c antibody responses to Gag and Env (Table 1) , recent studies document that the ecient expression of Gag and Env proteins depends upon the presence of cORF, probably as an export factor for unspliced HERV-K transcripts (Magin et al., 1999) . This suggests cORF expression in GCT regardless of the diculty with its detection. Generally, cORF expression appears to be very limited in many cell types, even upon transient transfection (our unpublished observations). Therefore, the protein levels required to trigger immune responses may not be reached in vivo. Whether cORF is actually expressed and functional in GCT and leukemias has to be examined in detail, and any connection between PLZF and cORF in leukemias has to be considered as highly speculative at present.
A further question of interest is whether PLZF, in turn, is involved in the development of GCT, perhaps via its connection with cORF. Remarkably, PLZFde®cient mice show no apparent disturbance in hematopoiesis but rather exhibit severe testicular dysfunction, among other defects (Barna et al., 2000; Hawe et al., 1996) . Furthermore, cyclin A has recently been identi®ed as one PLZF target gene, and cyclin A subtypes are considered to possess regulatory functions in murine spermatogenesis (Ravnik and Wolgemuth, 1999) . Malignant germ cell tumors in humans exhibit dierent states of dierentiation; they all, however, arise from the common (CIS/TIN) precursor lesion (Skakkebaek, 1972) , which already displays HERV-K(HML-2) expression (Herbst et al., 1998) . CIS cells resemble undierentiated gonocytes that normally dierentiate into spermatogonia in late fetal development (Skakkebaek et al., 1987) , and any delay in gonocyte maturation seems to be associated with an increased risk of testicular germ-cell cancer (Heimdal et al., 1997) . This and the development of GCT in men early in life (peak incidence: 25 ± 35 years of age) nurtures the suggestion that GCT neoplasms are initiated before birth. Hence, a disturbed spermatogenesis may well underly GCT and may involve PLZF and cORF.
Materials and methods
Plasmids pLRNL-gag, pLRNL-env and pLRNL-cORF were constructed by inserting the sequences coding for HERV-K Gag, HERV-K Env or HERV-K cORF into the BamHI-site of the retroviral expression vector pLRNL. This vector furthermore contains the long terminal repeats (LTRs) of Moloney murine sarcoma virus and a neomycin phosphotransferase (neoR) gene controlled by the Rous sarcoma virus promoter. The same cORF sequence was inserted into the run-o transcription vector pGEM1 for generation of in situ hybridization RNA probes. The gag and env probes were as previously described (Herbst et al., 1996) . Plasmid pCEP4-cORF was constructed by inserting full-length cORF into the BamHI-site of pCEP4 (Invitrogen). The same fragment was inserted in frame into the BamHI-site of pGEX-4T-1 (Pharmacia Biotech) to generate pGEX-cORF. Vector pNLexA-cORF was constructed by ampli®cation of a cORF fragment with primers [A]: 5'-ACTAGACATT TGAgcggccgcAATGAACCCATC-3' and [B]: 5'-ACAAAACCACCATCggatccATGG CCCGTTCT-3' that introduce restriction sites (lowercase letters) for NotI and BamHI, respectively. The fragment was digested with NotI and BamHI and ligated in frame into the NotI-and BamHI-sites of pNLexA. pJG4-5-cORF and pJG4-5-cORF mutants were constructed by PCRampli®cation of full-length cORF or the desired fragments, respectively, from the pCEP4-cORF template with primers that introduce restriction sites for EcoRI at the 5'-end and XhoI at the 3'-end. The ampli®ed fragments were ligated in frame into the EcoRI-and XhoI-sites of pJG4-5. 
Viral infections
Retroviruses were produced on 293GP producer cells and pseudotyped with VSV-G protein as described (Yee et al., 1994) . To establish Rat-1 cell lines stably expressing HERV-K genes, Rat-1 cells were seeded in a 75 cm 2 tissues culturē ask to approximately 10% con¯uence. The cells were infected with 5610 3 colony forming units (c.f.u.) of the pseudotyped retroviral vector stock in the presence of 8 mg/ ml polybrene for 4 h. Fresh medium containing 400 mg/ml G418 was added 48 h after infection until colonies appeared.
Tumorigenicity assays
Assays were performed by subcutaneous injection of 100 ml of a cell suspension containing 8610 5 cells into athymic nude mice (Balb/c). Control and transduced cells were injected into the¯anks of each mouse. Mice were monitored twice per week. After 6 weeks the mice were sacri®ced and the tumors were analysed.
Antibodies
To raise antisera, cORF was expressed in the pATH vector system. For polyclonal antisera, rabbits were immunized with cORF protein as described (Mueller-Lantzsch et al., 1993) . For monoclonal antibodies, cORF-protein was injected into Lou/c rats and antibodies were generated as described previously .
Western blot and zone velocity analyses
To test for cORF protein expression, Raji-cORF cells or Raji-control cells were brie¯y sonicated in SDS-gel loading buer (125 mM Tris/HCl pH 6.8, 6.3 % (w/v) SDS, 10 % (v/ v) 2-mercapto-1,2-propanediol, 10% (v/v) glycerol), boiled for 5 min and centrifuged (12 000 r.p.m.) for 20 min at 48C to remove cellular debris. Fifteen mg of total protein was loaded per lane on a 15% SDS/polyacrylamide gel (following standard protocols) and blotted onto nitrocellulose membrane. Blots were blocked in 5% non-fat dried milk in phosphate buered saline (PBS) pH 7.4 for 30 min and incubated overnight at 48C with primary antibodies (polyclonal a-cORF 3086 antiserum or pre-serum, diluted 1 : 100 in 5% milk-PBS). After three washes for 20 min each in PBS, blots were incubated with the secondary antibody (peroxcORF transforms cells and binds PLZF A Boese et al idase-conjugated goat anti-rabbit antibody, Sigma) in a dilution of 1 : 500 in 5% milk-PBS for 1 h at 48C. Blots were then washed as above and then subjected to enhanced chemiluminescence immunodetection (Amersham) according to the manufacturer's protocol. To obtain native extracts, cells were washed once in PBS, lysed for 30 min on ice in lysis buer (100 mM Tris/HCl pH 8.0, 100 mM NaCl, 5 mM KCl, 0.5 mM MgCl 2 , 1 mM CaCl 2 , 0.5% Nonidet P40, 1 mM dithiothreitol, 10 mg/ml aprotinin) and cellular debris was removed by centrifugation. Cellular lysate from 2610 7 RajicORF cells in a volume of 0.3 ml was layered on top of a 10.6 ml linear 5 ± 30% glycerol density gradient in gradient buer (10 mM HEPES pH 7.8, 5 mM Na3PO4 pH 7.8, 5 mM KCl, 0.5 mM MgCl 2 , 1 mM dithiothreitol and 20 mg/ml aprotinin). The gradient was run in a Beckman ultracentrifuge (SW41 rotor) for 11 h at 260 000 g and 48C. Fifteen fractions were collected by bottom puncture and protein was precipitated at 7708C for 45 min with a twofold volume of ethanol. The pellet was resuspended in 50 ml SDS-gel loading buer of which 15 ml were analysed by Western blotting. An aliquot of the non-fractionated, native Raji-cORF lysate mixed 1 : 1 with SDS-gel loading buer or SDS-gel loading buer-extracts from Raji-cells served as positive controls.
Immunofluorescence
For determination of antibody titers against HERV-K (HML-2) cORF, SF158 cells in logarithmic phase were infected with recombinant baculovirus. Wild-type baculovirus-infected cells served as controls. Insect cells expressing HERV-K cORF were prepared for immuno¯uorescence as described previously .
In situ hybridization and immunohistology
In situ hybridization was carried out as previously described (Herbst et al., 1996) . cORF protein was detected with the above speci®ed polyclonal and monoclonal antibodies on paran sections from nude mice tumors and human GCT samples by the APAAP technique, using mouse anti-rabbit Ig antibodies, mouse anti-alkaline phosphatase antibodies and rat anti-alkaline phosphatase antibodies.
Yeast two-hybrid, GST-pulldown and immunoprecipitation assays
A human testis activation domain (pJG4-5) cDNA library (MATCHMAKER LexA Libraries, Clontech) was screened using the yeast strain EGY48 and pNLexA-cORF as a bait according to the manufacturer's protocol. Plasmids from yeast clones showing speci®c activation of the reporter system were recovered, transfected into E. coli, and clones that carry pJG4-5 plasmids and encode putative cORF-interacting proteins were isolated and retransformed with pNLexAcORF into the EGY48 yeast strain to study reporter gene activation. To test for protein interactions, the appropriate pair of plasmids was co-transfected into strain EGY48 using the lithium acetate/polyethylene glycol method according to the Clontech Matchmaker protocol. Yeast clones were classi®ed positive if reporter-genes (lacZ, LEU2) were activated only in the presence of galactose but not of glucose, that inhibits expression from the plasmid pJG4-5 (internal negative control). The yeast strain EGY48 as well as reporter-and control-plasmids were generous gifts of Roger Brent. Glutathione S-transferase (GST) proteins or GSTfusion proteins were generated by transforming E.coli with plasmids pGEX-4T-1 or pGEX-4T-1-cORF. Exponentially growing cultures were induced with isopropyl-1-thio-b-Dgalactopyranoside for 4 h at 378C and cell pellets of 50 ml bacterial culture were resuspended in 5 ml GST lysis buer (20 mM Tris/HCl pH 7.5, 200 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol, 0.1 mM phenylemethylesulfonyl¯uoride) and stored at 7208C. A thawed suspension was sonicated for 1 min and cleared by centrifugation; supernatant was then added to glutathione-agarose beads (1/20 volume) and incubated for 1 h at 48C with gentle shaking. Beads were collected by centrifugation and washed three times in GST lysis buer.
35
S-labelled PLZF was synthesized in vitro using the pSG5-PLZF plasmid in the rabbit-reticulocyte lysate based TNT T7-coupled in vitro-transcription and -translation system (Promega) with 35 S-labeled methionine according to the manufacturer's recommendation. Thirty-®ve ml of protein-coated agarose beads (GST or GST-cORF) were incubated with 200 ml of native lysate from Raji-cells and 5 ml of radiolabeled PLZF protein for 1 h on ice. Pellets were then washed six times with GST lysis buer and boiled for 5 min in SDS-gel loading buer. The supernatant was loaded onto a 10% SDS/polyacrylamide gel. The gel was ®xed (50% (v/v) methanol, 10% (v/v) acetic acid) for 1/2 h, washed three times for 20 min in H 2 O and incubated for 1 h in 1 M Nasalicylat before drying. Ten per cent of in vitro translated PLZF protein input (0.5 ml) in 10 ml of SDS-gel loading buer was used as control. PLZF protein was immunoprecipitated from cellular lysate of 10 7 Raji (or Raji-cORF) cells in 500 ml of lysis buer, at 24 h after electroporation of 10 mg pSG5 (or pSG5-HA-PLZF) plasmid and by addition of 50 ml of monoclonal anti-PLZF (Calbiochem) antibody (or 50 ml of lysis buer as a control), 1 h incubation on ice and addition of 15 ml of protein G sepharose (PGS, 1 : 1 in PBS). After overnight incubation at 48C, PGS beads were collected by centrifugation and washed six times in lysis buer. Protein was released from the PGS by addition of sample buer and boiling for 5 min, half of the post-centrifugation supernatant was loaded onto one of two gels to check for PLZF and cORF presence in Western blot analysis.
